Tobiah Clukey
Family · Oceanside, CANPI 1306525662
Payments from drug & device makers
Across 174 payments — averaging $28.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$960
- Johnson & Johnson$745
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$712
- Takeda Pharmaceuticals U.S.A., Inc.$670
- Phathom Pharmaceuticals, Inc.$307
- Regeneron Healthcare Solutions, Inc.$289
- plus $1K from 14 others
What the payments were for
- Food & beverage$4,71397%
- Education$1683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $960 |
| Johnson & Johnson | 27 | $745 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $712 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $670 |
| Phathom Pharmaceuticals, Inc. | 8 | $307 |
| Regeneron Healthcare Solutions, Inc. | 7 | $289 |
| Sanofi | 8 | $251 |
| Lilly USA, LLC | 9 | $248 |
| Pfizer | 3 | $186 |
| Madrigal Pharmaceuticals | 9 | $141 |
| Aimmune Therapeutics, Inc. | 1 | $93 |
| Intercept Pharmaceuticals, Inc. | 3 | $70 |
| Ardelyx, Inc. | 3 | $70 |
| Braintree Laboratories, Inc. | 2 | $37 |
| Novo Nordisk | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $19 |
| Celltrion USA Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| QOL Medical, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,881 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 11 | $6,676 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 75 | $4,543 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 36 | $518 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $303 |
| Famotidine | 12 | $224 |
| Omeprazole | 19 | $126 |
| Pantoprazole Sodium | 12 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $960 | $6,67611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Oceanside
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.